Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions
Mitchell Nides1, Scott Leischow, Linda Sarna
1Los Angeles Clinical Trails, Los Angeles, CA 90025, USA. mnides@laclinicaltrails.com
Clinicians can significantly reduce patient cardiovascular disease by advising smoking cessation and prescribing pharmacotherapy. Referral to telephone quitlines and hospital-based programs enhances success rates for patients quitting smoking.
Area of Science:
- Public Health
- Cardiovascular Medicine
- Addiction Medicine
Background:
- Smoking cessation is a critical intervention for reducing cardiovascular morbidity and mortality.
- Clinicians play a vital role in assisting patients to quit smoking.
- Current clinical practices often lack comprehensive smoking cessation support.
Purpose of the Study:
- To outline strategies for clinicians to effectively promote smoking cessation.
- To highlight the role of pharmacotherapy and behavioral counseling in quitting.
- To recommend system-level interventions for improving cessation support.
Main Methods:
- Review of current clinical guidelines and evidence on smoking cessation.
- Emphasis on clinician-delivered interventions including advice and pharmacotherapy.
- Recommendation for referral to specialized services like telephone quitlines.
- Proposal for hospital-wide implementation of cessation protocols.
Main Results:
- Pharmacotherapy (nicotine replacement, bupropion, varenicline) can double cessation success rates.
- Behavioral counseling and extended follow-up are crucial but often lacking.
- Telephone quitlines offer accessible, expert-led behavioral support.
- Inpatient consultations with follow-up improve quit rates.
Conclusions:
- Integrating smoking cessation into routine clinical practice is essential.
- Pharmacotherapy combined with behavioral support maximizes quit rates.
- System-level changes, including hospital protocols and quitline referrals, are necessary for comprehensive care.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Acute Coronary Syndrome IV: Interprofessional Care
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
COPD: Management Using Bronchodilators and Corticosteroids
CNS Depressants: Alcohol and Nicotine
